Print

Apricus Biosciences (APRI) Submits Response to Swissmedic for Its Vitaros(R) Market Application for Erectile Dysfunction  
6/14/2012 9:48:19 AM

SAN DIEGO, June 14, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or "the Company") (Nasdaq:APRI) (www.apricusbio.com) today announced that the Company has filed its response to questions received from Swissmedic, the Agency for Therapeutic Products in Switzerland, relating to its marketing application previously filed for VitarosĀ®, the Company's lead product candidate for the treatment of erectile dysfunction ("ED") in Switzerland.
//-->